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CONCLUSION: Managerial strategies can be developed
to control some of the increasing costs by promoting the
use of cost-effective therapies for optimum outcomes but
pharmacy beneﬁt costs will continue to escalate because
of an increasing proportion of recipients and intensity per
recipients and compounded by an aging population.
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OBJECTIVES: The American Productivity Audit (APA),
an on-going week-to-week telephone survey, provides
valid and reliable estimates of health-related lost produc-
tive work time. This paper describes the APA and identi-
ﬁes the ﬁve most costly episodic/chronic-episodic health
conditions.
METHODS: We developed and validated the Work 
and Health Interview (WHI) for APA administration. The
WHI quantiﬁes missed work hours and lost produc-
tive time while at work for speciﬁc health conditions
using two-week recall. Two measures were derived for
each condition—hours/worker/week of lost productive
time (LPT) and its dollar equivalent. Several derivation
methods were considered. We selected a conservative
method based on self-reported attribution for LPT. A
random sample of 13,252 workers 18–65 years of age,
selected using Random-Digit-Dialing, completed the 
WHI by phone in their homes between July 2, 2001 and
January 2, 2002. LPT was converted to dollars/worker/
week using self-reported annual salary.
RESULTS: Among all respondents, mean LPT from
episodic/chronic-episodic conditions was 1.6 hours/
worker/week (1.8 hours/week for women; 1.4 hours/week
for men). Thirty-three percent reported LPT from >1 of
16 different episodic/chronic-episodic conditions. The
prevalence of the ﬁve conditions associated with the most
LPT/worker/week was cold/ﬂu (8.9%), headache (7.3%)
back pain (3.9%), low energy (3.7%), and arthritis
(2.7%). LPT attributed to each condition among those
affected was cold/ﬂu (0.43), headache (0.23), back pain
(0.20), low energy (0.14), and arthritis (0.13). Extrapo-
lating to the US workforce, the estimated cost of these
ﬁve health conditions to employers was approximately
$124.7 billion/year.
CONCLUSIONS: The APA provides national estimates
of health-related LPT. Results indicate that common con-
ditions like cold/ﬂu, headache, and back pain result in a
signiﬁcant but largely invisible ﬁnancial loss to employ-
ers. Findings may be subject to seasonality bias based on
only six months of data collection. Unbiased estimates
that we will benchmark to the Current Population Survey
will follow as we collect additional data.
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OBJECTIVE: To examine the CE of adding minipool
NAT to current blood screening (CS) of volunteer blood
donations to reduce the risk of HBV, HCV and HIV infec-
tion in the United States.
METHODS: We developed a decision analytic model 
of screening volunteer blood donations in the US based
on recently published Markov models of HBV, HCV, and
HIV infection to estimate discounted lifetime costs and
quality-adjusted life year (QALY) gains. Infection risk
(including prevalence and the window period between
antigen and antibody detectability in the donated blood),
and test sensitivities were derived from the literature. 
Age-speciﬁc ten-year survival of transfusion recipients
was from Vamvakas (1994) and the age distribution 
from a private managed care database for transfusions in
1995. Secondary analyses considered alternative screen-
ing strategies.
RESULTS: The model estimated NAT would annually
prevent 37, 128 and 7 transfusion-acquired cases of HBV,
HCV, and HIV respectively compared to CS alone (6.2
million transfusion recipients). HCV had the greatest
impact on total QALYs and costs. Although the cost per
case of HIV avoided was 3–4 times that for HBV or HCV,
the overall impact of HIV on CE was small. Adding NAT
to CS would add 86 life years, at an incremental cost per
life year gained of $2.1M and an incremental cost per
QALY gained of $1.2M. The CS + NAT-p24 strategy
dominated CS + NAT, and had an incremental cost per
QALY of $0.9M compared to CS. Results were most sen-
sitive to disease incidence rates, screening test costs, esti-
mates of window period closure, and the age distribution
of transfusion recipients.
CONCLUSIONS: The CE of adding NAT to current
screening, although not within a range considered cost-
effective for health care treatments, may be reasonable
when considered in the context of other blood-related
preventive interventions such as autologous blood 
donation, and the desire for a zero tolerance level for
infections from blood transfusions.
